ClinicalTrials.gg
Status unknownNCT02605603Updated Aug 13, 2019

SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease

An observational study in Gaucher Disease, sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc.. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-13.

Sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Gaucher Disease with a site in United States — 20 open to participants now, 27 under way, 2 of them phase 3. Gaucher Disease · United States.

Planned enrollment
28th of 39
30 · median 60
Started
2015
with 6 others
Observational
39 of 92
16 open now
Registered
53rd of 92
by date
Lead sponsor
5 of 92
Lysosomal and Rare Disorders Research and Treatment Center, Inc.

Among the 92 studies in Gaucher Disease with a site in United States, this one is the 28th largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2015, is one of 39 observational ones, and was the 53rd registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

20 of the 92 studies in Gaucher Disease with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Gaucher Disease with a site in United States, or all of them as a file.
02

Study summary

This project is expected to elucidate role of different therapeutic interventions: SRT in comparison to ERT in influencing immune aspects of GD pathology, as well as bone involvement.

Read the detailed description

Introduction

Lysosomes are small, cytoplasmic organelles that contain several acid hydrolase enzymes. These enzymes break down foreign materials and cellular debris allowing the lysosomes to act as recycling centers for the cells. Following DNA transcription, lysosomal enzymes are produced in the endoplasmic reticulum and targeted to lysosomes by specific recognition markers. If one of the enzymes is absent or if its function is diminished due to either an altered amino acid sequence of the protein or defective intracellular trafficking, the macromolecules metabolized by the specific enzyme will gradually accumulate in the lysosomes. Abnormal substrate storage leads to cellular dysfunction followed by cell death ultimately manifesting as tissue damage and organ failure.

Gaucher disease (GD) is a lysosomal storage disorder caused by a genetic deficiency of the lysosomal enzyme glucocerebrosidase. GD leads to accumulation of glycosphingolipids in various tissue systems, most notably in cells of mononuclear phagocyte system resulting in a wide range of heterogenous phenotypic effects in the affected individuals. Clinical manifestations of GD affect across multiple organs ranging from immune dysregulations, splenomegaly to bone crises and osteoporosis. Carrier frequency is 1 in 200 for the general population with an incidence of 1 in 60,000. However, in certain populations, such as Ashkenazi Jews, the incidence could be as high as 1 in 1,000.

Background and Significance

Macrophage directed Enzyme replacement therapy (ERT) has been the most accepted form of treatment for GD. However there are still unmet needs in treating all aspects of GD using ERT. As an alternative to ERT, substrate reduction therapy (SRT) was developed using glucosylceramide synthase inhibitors. While ERT is devised to target macrophages which are the most affected cell types, SRT is meant to reach broad cell types. It is vital to know how each form of therapy acts on different cell types and tissues while choosing to administer either form of treatment on individual patients. Our preliminary immune phenotyping results reveal that patients with GD undergoing treatment manifest various kinds of persistent immune dysregulations. Information regarding which type of therapy works better in controlling these dysregulations would give valuable information in treatment options. In-depth analysis on peripheral blood would shed light as to how various components of immune system are being affected with either form of treatment.

The investigators will address this issue from two aspects: a) Evaluate cytokine profile from plasma to see if the reported pain correlates with a particular cytokine profile. b) Assess if the extent of bone disease could be predicted or explained using markers from peripheral blood in relation to pathways involved in bone remodeling. The findings from individual GD patients would be compared in parallel to their disease severity and bone density findings.

In this study, the effects of ERT vs SRT will be closely monitored and compared, particularly keeping in mind immunological aspects as well as bone remodeling. For this, in-depth immunophenotyping of patients being administered these forms of therapy to evaluate various immune cell types including T-, B- and NK cell, monocyte and dendritic cell fractions from peripheral blood using multi-parametric flow cytometry will be performed. In addition to these the investigators will like to assess the macrophage activation using assays for secreted CCL18 and chitotriosidase as well as study the cytokine profile from plasma to evaluate their contribution to bone pain/crisis. In order to investigate if the extent of bone remodeling could be predicted or explained using markers from peripheral blood, expression of RANK/RANKL pathway components would be assessed on relevant immune cell types. Cell based in vitro assays would be developed and utilized to study differentiation and macrophage function. The results from individual GD patients would be compared in parallel to their disease severity and bone density findings. This proposal is highly significant and innovative, because this study is expected to provide insights into how each form of therapy influences the immune dysregulations, macrophage function and their effects on bone crisis in Gaucher patients undergoing ERT vs SRT. Insight regarding which type of therapy works better in controlling these dysregulations would give valuable information in treatment options.

03

Conditions studied

  • Gaucher Disease

Browse trials for

Keywords

  • Gaucher Type 1, Gaucher Type 2, Gaucher Type 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Gaucher disease, and are currently on Enzyme replacement therapy (ERT) or on Substrate reduction therapy (SRT).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of Gaucher disease
  2. Subjects on SRT using Cerdelga ( must fulfil the pharmacogenomics criteria for Cerdelga)

Exclusion criteria

Exclusion Criteria:

  1. Unconfirmed diagnosis of Gaucher disease
  2. Subject or guardian unable to provide consent
  3. Any chronic state or therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Delineate T-, B- and NK cell fractions as well as dendritic cell and monocyte numbers and compare between patients undergoing ERT vs. SRT.

    We will utilize multicolour flow cytometry using cell surface markers to perform detailed analysis of various components of immune system. Activation of monocytes/macrophages per se would be measured using secreted cytokines like CCL18 and chitotriosidase from plasma.

    Time frame: 2 Years

Secondary outcomes

  1. Comparative effects on skeletal involvement in individual Gaucher patients correlates with their disease severity and bone involvement.

    Bone mineral deposition will be examined by Alizarin Red staining.

    Time frame: 2 Years

Other outcomes

  1. The effect of Enzyme Replacement Therapy vs. Substrate Replacement Therapy.

    Monocytes would be identified as CD45+/CD14+ fraction from peripheral blood in GD patients undergoing ERT or SRT and compared to non- Gaucher controls.

    Time frame: 2 years

07

Study locations

1 site
  • O&O Alpan, LLC
    Fairfax, Virginia 22030, United States
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Feb 2020 and a completion of May 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2015
First posted
Nov 16, 2015
Start
May 2015
Primary completionEst.
Feb 2020
CompletionEst.
May 2020
Last update
Aug 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02605603
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2015
Start date
May 2015
Primary completion
Feb 2020 (estimated)
Completion
May 2020 (estimated)
Last update
Aug 13, 2019

Study contacts

Ozlem Goker-Alpan, MD
principal investigator · Study Principle Investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion